Michael Emig

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.4K citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +7

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet · 2009 · 1.4K citations · Full text

Medicine, Metronomic Therapy, Phase Iii Trial +7

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

Michael Emig, Susanne Saußele, H Wittor et al. · Leukemia · 1999 · 269 citations

Residual Disease, Engineering, Medicine +9

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Andreas Hochhaus, Andreas Reiter, Anja Reichert Susanne Saußele et al. · Blood · 2000 · 184 citations

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Robert Pirker, A. Szczęsna, Joachim von Pawel et al. · Journal of Clinical Oncology · 2008 · 173 citations

Cancer Management, Immunology, Pathology +19